Bayer to pay $1.6 billion to resolve U.S. claims for Essure birth-control device By Reuters

Bayer to pay $1.6 billion to resolve U.S. claims for


© Reuters. FILE PHOTO: The historic headquarters of German pharmaceutical and chemical maker Bayer AG is pictured in Leverkusen

FRANKFURT (Reuters) – German drugs and pesticides group Bayer (OTC:) said on Thursday it will pay around $1.6 billion to settle the majority of U.S. claims involving its Essure birth-control device.

The agreement follows a $10.9 billion settlement in June of U.S. lawsuits claiming the company’s weedkiller Roundup caused cancer.

Bayer said the Essure settlement is for around 90% of the nearly 39,000 claims by women alleging injury from the devices and that it was in discussion with counsel for the remaining plaintiffs.

“There is no admission of wrongdoing or liability by Bayer in the settlement agreements,” Bayer said.

Women have claimed in lawsuits that the device, which is implanted in the fallopian tubes to permanently block the passage of eggs to the uterus, could pierce the tubes, and that the device’s metal parts could become dislodged and migrate to other parts of the body.

Bayer said in 2018 that it would phase out the birth control product in the United States, a decision which the company said was due to declining sales of the implantable device and not based on safety concerns.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *


About us

InvestLab is a financial services technology company focused on the global trading market. Founded in 2010 in Hong Kong, the company develops trading, market data, and social research products that enable individual investors and small to mid-size brokers to access global markets. We provide brokers and financial institutions cross border capabilities for retail investors into 43 markets globally.


CONTACT US

CALL US ANYTIME